- Home
- OCFC vs GHRS Comparison
OCFC vs GHRS Comparison
Compare OCFC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCFC | GHRS |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OCFC | GHRS |
|---|---|---|
| Price | $19.66 | $29.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $21.67 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 898.1K | 309.6K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.51 | N/A |
| Revenue Next Year | $21.97 | N/A |
| P/E Ratio | $72.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $11.83 |
| 52 Week High | $20.61 | $31.44 |
Technical Indicators
Market Signals| Indicator | OCFC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 56.74 |
| Support Level | $19.03 | $25.66 |
| Resistance Level | $20.06 | $31.22 |
| Average True Range (ATR) | 0.38 | 1.43 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 66.53 | 54.46 |
Price Performance
Historical ComparisonAbout OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.